Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model by Yoshida, K. et al.
1SCIentIFIC RepoRtS |  (2018) 8:3896  | DOI:10.1038/s41598-018-21369-y
www.nature.com/scientificreports
Adenovirus-prime and baculovirus-
boost heterologous immunization 
achieves sterile protection against 
malaria sporozoite challenge in a 
murine model
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With the increasing prevalence of artemisinin-resistant malaria parasites, a highly efficacious and 
durable vaccine for malaria is urgently required. We have developed an experimental virus-vectored 
vaccine platform based on an envelope-modified baculovirus dual-expression system (emBDES). 
Here, we show a conceptually new vaccine platform based on an adenovirus-prime/emBDES-boost 
heterologous immunization regimen expressing the Plasmodium falciparum circumsporozoite 
protein (PfCSP). A human adenovirus 5-prime/emBDES-boost heterologous immunization regimen 
consistently achieved higher sterile protection against transgenic P. berghei sporozoites expressing 
PfCSP after a mosquito-bite challenge than reverse-ordered or homologous immunization. This 
high protective efficacy was also achieved with a chimpanzee adenovirus 63-prime/emBDES-boost 
heterologous immunization regimen against an intravenous sporozoite challenge. Thus, we show that 
the adenovirus-prime/emBDES-boost heterologous immunization regimen confers sterile protection 
against sporozoite challenge by two individual routes, providing a promising new malaria vaccine 
platform for future clinical use.
Malaria remains a severe public health problem and causes significant economic losses worldwide. Nearly half the 
world’s population is at risk of malaria, with a disproportionate risk and high mortality in children under 5 years 
old. In 2016, there were approximately 216 million cases of malaria and an estimated 445,000 malaria deaths1. The 
World Health Organization recommends the use of artemisinin as the core compound of a combination treat-
ment, but artemisinin resistance is already present in some countries in South-East Asia1. A malaria vaccine is 
an attractive alternative to drug treatment or prophylaxis. The most advanced candidate Plasmodium falciparum 
malaria vaccine, RTS,S/AS01 (also known as Mosquirix™), based on the P. falciparum circumsporozoite protein 
(PfCSP) targeting the pre-erythrocytic stage, conferred limited protection (18–26% in infants) in a phase III trial 
in sub-Saharan Africa2,3. Although the mechanism of the RTS,S/AS01-induced protective immune response has 
not been clarified in detail, the CSP-specific antibodies (Abs) and CD4+ T-cell responses induced by vaccination 
with RTS,S/AS01 have been correlated with protection4,5. To improve the protective efficacy of RTS,S/AS01, an 
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adenovirus 35 prime and RTS,S/AS01 boost heterologous immunization regimen followed by another booster 
dose of RTS,S/AS01 (ARR) was tested in humans6. Although ARR immunization enhanced the CD4+ and CD8+ 
T-cell responses better than three doses of RTS,S/AS01 (RRR), the protective efficacy of ARR immunization 
did not exceed that of RRR immunization6,7. Future strategies that surpass RTS,S/AS01-induced protection may 
require alternative highly immunogenic prime-boost regimens and/or additional target antigens. Therefore, the 
development of viral vectors as vaccine platforms continues to be important.
We have developed a new viral-vectored vaccine system based on the baculovirus Autographa californica 
nucleopolyhedrosis virus, called the ‘baculovirus dual-expression system’ (BDES). BDES drives the expression of 
malaria antigen with a dual promoter that consists of both baculovirus-derived polyhedrin and mammal-derived 
cytomegalovirus promoters, which allow the antigen to be displayed in its native conformation on the viral enve-
lope and to be expressed after the transduction of mammalian cells, respectively8. Therefore, BDES functions as 
both a component vaccine and a DNA vaccine. We have shown that BDES is an effective malaria vaccine platform 
for all three stages of the Plasmodium life cycle, including the pre-erythrocytic stage8–10, asexual blood stage11,12, 
and sexual stage9,13–15, when transgenic P. berghei parasites expressing human Plasmodium antigens were used 
for its evaluation. In addition to the high efficacy of BDES demonstrated in these experiments, BDES-based 
PfCSP vaccines (BDES-PfCSP) have been shown to be safe and well tolerated in Rhesus monkeys, with accept-
able reactogenicity and systemic toxicity10. More recently, we have generated an envelope-modified BDES 
(emBDES-PfCSP) pre-erythrocytic-stage vaccine, which displays both human decay-accelerating factor (DAF) 
and P. falciparum circumsporozoite protein (PfCSP) on the virion surface16. The DAF-shielded emBDES induced 
enhanced resistance to serum inactivation, and when combined with an interleukin 12 (IL-12)-expressing bacu-
lovirus vaccine (emBDES-PfCSP/IL12), further enhanced the protective efficacy against sporozoite challenge in 
a murine model after two or three boosts17. However, to ensure its subsequent field application and improve its 
cost-effectiveness, a simpler immunization regimen (e.g., vaccine dose) and improved protective efficacy in terms 
of the T-cell-mediated immune responses are required.
Several studies have shown the efficacy of heterologous prime-boost immunization strategies in inducing 
T-cell-mediated immunity against a variety of pathogens, including Mycobacterium tuberculosis18–23, human 
immunodeficiency virus24,25, and Ebola virus26,27. Researchers in malaria at the Jenner Institute (University 
of Oxford, Oxford, UK) have demonstrated that a heterologous prime-boost immunization regimen using a 
replication-deficient chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) increased 
the number of antigen-specific CD8+ T cells, improving the protective efficacy in mouse and macaque mod-
els28–30. It is widely recognized that a successful pre-erythrocytic malaria vaccine must induce not only humoral 
immune responses but also CD8+ T-cell-mediated immune responses31–35 to inhibit the infection of the liver by 
sporozoites and to eliminate any resulting liver-stage parasites that develop in hepatocytes.
In this study, we combined the baculoviral-vectored vaccine, emBDES-PfCSP/IL12, with a human adeno-
virus 5 (AdHu5)-based PfCSP vaccine (AdHu5-PfCSP) or ChAd63-based PfCSP vaccine (ChAd63-PfCSP) to 
determine whether the protective efficacy was improved, and to identify immunological surrogates for protec-
tion. We demonstrate that the new vaccine platform using an adenovirus-prime and emBDES-boost regimen 
elicited higher protective efficacy against sporozoite challenge than the reverse-ordered or homologous immu-
nization. This immunization regimen also functions as a ‘hybrid’ vaccine platform that effectively induces both 
humoral and cellular immune responses. These findings illustrate a novel hybrid malaria vaccine based on an 
adenovirus vaccine and an emBDES vaccine, which has unique anti-parasite advantages and potential utility as a 
‘next-generation’ clinical candidate vaccine against other emerging and re-emerging infectious diseases.
Results
Reduction of transgene expression following re-administration of a baculoviral vector. We 
have previously shown that emBDES-PfCSP/IL12 requires 3–4 doses of immunization to elicit 60–80% sterile 
protection against sporozoite challenge17. To examine the transduction efficacy of baculovirus in vivo after its 
re-administration, BES-GL3 expressing the luciferase gene was administered into the right tibialis anterior mus-
cle of BALB/c mice (1 × 108 PFU/mouse; n = 3) on day 0. Luciferase expression was monitored with biolumines-
cence imaging (Fig. 1A), and the data for the total flux (Fig. 1B) at different time points were normalized against 
the total flux after 3 h (defined as 100%). The expression of luciferase was initially robust but rapidly decreased 
to 2% on day 7 and had disappeared on day 42. When BES-GL3 was re-administered into the left tibialis anterior 
muscle on day 56, its expression (56d + 3 h) was severely impaired, decreasing to almost 1% of that at 3 h after 
the first administration into the right tibialis anterior muscle (p < 0.05, Student’s t-test) (Figs. 1A and B). Similar 
to the results for other viral vectors, these results indicate that multiple administrations of baculovirus dampen 
the vaccine-antigen-specific booster response because the vector itself is rapidly cleared by the immune system 
induced by the prime immunization.
High levels of PfCSP expression by AdHu5-PfCSP on the surface of infected cells. To over-
come the potential problem caused by multiple administrations of baculovirus, we investigated a new 
prime-boost immunization regimen using emBDES in combination with other vaccine vectors. We first 
chose replication-deficient AdHu5 as the partner of emBDES because the recombinant AdHu5 is one of the 
most efficient vectors in inducing T-cell responses, which may play an important role in the elimination of 
pre-erythrocytic parasites.
We constructed an AdHu5-PfCSP vaccine carrying the same gene cassette as emBDES-PfCSP, which encodes 
a glycosylphosphatidylinositol (GPI)-anchor lacking PfCSP (Leu19-Val377) fused to the VSV-G protein mem-
brane anchor sequence, followed by a wpre sequence, under the control of the CAG promoter. Immunoblotting 
showed that AdHu5-PfCSP [multiplicity of infection (MOI) = 1] expressed similar levels of the PfCSP-VSV-G 
fusion protein, with the predicted Mr of 53 kDa, as emBDES-PfCSP (MOI = 100) (Fig. 2A, lanes 1 and 2) and 
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emBDES-PfCSP incorporated PfCSP into the viral virion (Fig. 2A, lane 3). In an indirect immunofluorescent 
antibody (IFA) staining, non-permeabilized cells infected with AdHu5-PfCSP (MOI = 1) or transduced with 
emBDES-PfCSP (MOI = 100) were incubated with an anti-PfCSP monoclonal antibody (mAb) 2A10 conjugated 
with Alexa Fluor 594. As expected, strong immunofluorescent signals were detected on the surfaces of both the 
AdHu5-PfCSP-infected and emBDES-PfCSP-transduced cells, indicating that VSV-G was anchored to the cell 
membranes (Fig. 2B,C).
Immunogenicity of heterologous prime-boost regimens using AdHu5-PfCSP and 
emBDES-PfCSP/IL12. The humoral and cellular immune responses induced by a heterologous regimen 
with AdHu5-PfCSP-prime/emBDES-PfCSP/IL12-boost were compared with those induced by a homologous 
regimen with either AdHu5-PfCSP or emBDES-PfCSP/IL12. Mice were immunized with various heterologous or 
homologous regimens using AdHu5-PfCSP and emBDES-PfCSP/IL12 at 3-week intervals. Two weeks after boost-
ing, their sera were collected and the anti-PfCSP IgG antibody (Ab) titres were measured with an enzyme-linked 
Figure 1. Reduction in the transduction efficacy of baculovirus in vivo after re-administration. (A) Luciferase 
expression at different time points, detected by using the IVIS Lumina LT Series III In Vivo imaging system. 
Luciferase-expressing BES-GL3 was administered into the right tibialis anterior muscle of BALB/c mice 
(n = 3; 1 × 108 pfu/mouse) on day 0. Luciferase expression was reduced to an undetectable level on day 42, and 
BES-GL3 was re-administered into the left tibialis anterior muscle on day 56 (14 days later). (B) Quantitative 
analysis of luciferase expression. Total flux at different time points was normalized to that at 3 h and is expressed 
as relative total flux. Asterisks indicate a significant difference (p < 0.05) on Student’s t-test compared with first 
administration at that time point.
www.nature.com/scientificreports/
4SCIentIFIC RepoRtS |  (2018) 8:3896  | DOI:10.1038/s41598-018-21369-y
immunosorbent assay (ELISA). The highest anti-PfCSP immunoglobulin G (IgG) Ab titre was induced 
when the homologous regimen with AdHu5-PfCSP was administered (Fig. 3A). The AdHu5-PfCSP-prime/
emBDES-PfCSP/IL12-boost regimen induced significantly higher anti-PfCSP IgG Ab titres than did the 
emBDES-PfCSP/IL12-prime/AdHu5-PfCSP-boost regimen (Fig. 3A).
Similar to the humoral responses, the cellular immune responses, examined with intracellular cytokine 
staining (ICS) assays, showed that homologous regimen with AdHu5-PfCSP induced the highest interferon 
γ (IFN-γ) production by CD8+ T cells after stimulation with the CSP-derived H-2Kd peptide (Fig. 3B and 
Supplementary Fig. S1). The heterologous regimen with AdHu5-PfCSP and emBDES-PfCSP/IL12 induced 
significantly higher IFN-γ production than the homologous regimen with emBDES-PfCSP/IL12 (Fig. 3B). Ex 
vivo IFN-γ enzyme-linked immunosorbent spot (ELISPOT) assays also showed similar frequency patterns 
of IFN-γ-secreting cells [means of spot forming units (SFU) per million splenocytes: AdHu5-PfCSP, 2,648 > 
emBDES-PfCSP/IL12-prime/AdHu5-PfCSP-boost, 2,378 > AdHu5-PfCSP-prime/emBDES-PfCSP/IL12-boost, 
1,162 > emBDES-PfCSP/IL12, 3.3] (Fig. 3C). These results indicate that emBDES-PfCSP/IL12 immunization 
with AdHu5-PfCSP as either the primary or booster immunization induces markedly stronger PfCSP-specific Ab 
and CD8+ T-cell responses than the homologous regimen with emBDES-PfCSP/IL12.
Protective efficacy of heterologous prime-boost regimens using AdHu5-PfCSP and 
emBDES-PfCSP/IL12 against mosquito-bite challenge. The protective efficacy of various heter-
ologous and homologous prime-boost regimens using AdHu5-PfCSP and emBDES-PfCSP/IL12 was assessed 
by challenging immunized mice with the natural bites of mosquitoes infected with transgenic PfCSP-Tc/Pb 
sporozoites expressing full-length PfCSP. Although in this biting challenge the challenge dose presented to the 
mice is highly variable, there were no significant differences in the number of infectious bites among the groups 
(Supplementary Table S1). In each challenge, the AdHu5-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen 
consistently conferred high sterile protection (50–100%), with a mean protective efficacy of 77% (Table 1). The 
reverse-ordered vaccination (emBDES-PfCSP/IL12-prime/AdHu5-PfCSP-boost) and homologous AdHu5-PfCSP 
regimens both displayed lower protective efficacy (each 20%; Table 1, Experiment 1). Among all the immuniza-
tion groups, there was no significant correlation between the protection level and the PfCSP-specific immune 
responses (anti-PfCSP Ab titres and IFN-γ production). To identify surrogate marker(s) for protective efficacy, 
sera obtained from the group of mice immunized with the heterologous AdHu5-PfCSP-prime/emBDES-PfCSP/
IL12-boost regimen before challenge were divided into the protected and unprotected groups, and their isotype 
IgGs were analysed (Fig. 4). Figure 4C shows that the protected mice had significantly higher anti-PfCSP IgG2a 
Figure 2. Expression of PfCSP in mammalian cells. (A) Immunoblotting analysis of HEK293A cells infected 
with AdHu5-PfCSP (MOI = 1) (lane 1), or transduced with emBDES-PfCSP (MOI = 100) (lane 2) or emBDES-
PfCSP viral particles (1 × 106 pfu) (lane 3). Cells or viral particles were lysed, loaded onto a 10% SDS-PAGE and 
immunoblotted with anti-PfCSP mAb 2A10. M, molecular marker. (B) HEK293A cells (3 × 104) were infected 
with AdHu5-PfCSP (MOI = 1). (C) HEK293A cells were transduced with emBDES-PfCSP (MOI = 100). After 
48 h, the cells were fixed with 4% paraformaldehyde, and incubated with Alexa-Fluor-594-conjugated anti-
PfCSP mAb 2A10. Cell nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI; blue). Original 
magnification, ×400. Bars = 50 μm.
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Figure 3. PfCSP-specific Abs and cellular immune responses in mice immunized with heterologous prime-
boost regimens using AdHu5-PfCSP and emBDES-PfCSP/IL12. (A) Anti-PfCSP IgG Ab responses. BALB/c 
mice were immunized with the indicated regimens. AdHu5-PfCSP and emBDES-PfCSP/IL12 are shown as 
AdHu5 and emBDES, respectively. Two weeks after boosting, individual sera were collected and their anti-
PfCSP IgG Ab titres were determined with ELISA (Data from experiment 1 are shown in Table 1). Bars and 
error bars indicate the means and SD of the values, respectively. Between-group differences were assessed 
with the Kruskal-Wallis test with Dunn’s correction for multiple comparisons. ****p < 0.0001, **p < 0.01, 
and *p < 0.05. (B,C) PfCSP-specific cellular immune responses. Two weeks after boosting with the indicated 
regimens, splenocytes were stimulated with the synthetic PfCSP-specific CD8 T-cell epitope. (B) An ICS assay 
was performed on the splenocytes. Percentages of IFN-γ-secreting cells in the CD8+CD4− T-cell population 
are shown after the subtraction of the percentages of cells stained with an isotype control Ab. Bars and error 
bars indicate means and SD, respectively; n = 3 or 4. Between-group differences were assessed with the Kruskal-
Wallis test with Dunn’s correction for multiple comparisons. ****p < 0.001, compared with naïve splenocytes 
stimulated with the same epitope. (C) An ex vivo ELISPOT assay was performed on splenocytes from the same 
mice. The IFN-γ SFU that reacted with the PfCSP-specific CD8 T-cell epitope per million splenocytes are 
shown. Bars and error bars indicate the mean numbers and SD, respectively. Between-group differences were 
assessed with the Kruskal-Wallis test with Dunn’s correction for multiple comparisons. *p < 0.05, compared 
with naïve splenocytes; n = 3 or 4.
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Ab titres than the unprotected mice (p = 0.0359). No correlation was observed between protection and the total 
IgG, IgG1 nor IgG2b Ab levels (Figs. 4A, B and D).
Immunogenicity of heterologous prime-boost regimens using ChAd63-PfCSP and emBDES-PfCSP/
IL12. Although the heterologous AdHu5-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen was highly protective, 
Prime Boost
Number of protected mice (%)
Expt. 1 Expt. 2 Expt. 3 Overall
BES-GL3 BES-GL3 0/11 (0) 0/10 (0) 2/7 (29) 2/28 (7)b
emBDES emBDES 0/10 (0) — — 0/10 (0)
emBDES AdHu5 2/10 (20) — — 2/10 (20)
AdHu5 emBDES 5/10 (50)c 12/15 (80)c 9/9 (100)c 26/34 (77)b,c
AdHu5 AdHu5 2/10 (20) — — 2/10 (20)
Table 1. The protective efficacy of heterologous prime-boost regimens using AdHu5 and emBDES against 
challenge by the bites of mosquitoes infected with PfCSP-Tc/Pb parasites in the vaccinated micea. aAdHu5-
PfCSP and emBDES-PfCSP/IL12 are showed as AdHu5 and emBDES, respectively. Mice were checked for 
PfCSP-Tc/Pb blood-stage infections by microscopic examination of Giemsa-stained thin smears of tail blood 
after challenge infections. Protection is defined as the complete absence of blood-stage parasitaemiae on day 14 
post-challenge. bCumulative data from three independent experiments. cEach group of immunized mice was 
compared with the control group (BES-GL3) to test for statistically significant differences using Fisher’s exact 
probability test (p < 0.01).
Figure 4. Comparison of anti-PfCSP IgG isotype Ab titres in mice immunized with AdHu5-PfCSP-prime/
emBDES-PfCSP/IL12-boost regimen. All anti-PfCSP IgG isotype Ab titre data from mice immunized with 
AdHu5-prime/emBDES-boost regimen shown in Table 1 were combined and plotted separately for the 
protected (P) mice (n = 26) and unprotected (NP) mice (n = 8). Anti-PfCSP total IgG (A), IgG1 (B), IgG2a (C), 
and IgG2b Ab titres (D) are shown. Bars indicate mean values. The p values were determined with the Mann-
Whitney test.
www.nature.com/scientificreports/
7SCIentIFIC RepoRtS |  (2018) 8:3896  | DOI:10.1038/s41598-018-21369-y
one of the major problems with AdHu5 is the high seroprevalence of anti-AdHu5 Abs in the human population, par-
ticularly in sub-Saharan Africa36, where a malaria vaccine is urgently needed. Therefore, we next tested an alternative 
adenovirus, replication-deficient chimpanzee adenovirus 63 (ChAd63), because ChAd63 has an excellent safety profile 
with low levels of pre-existing neutralizing Abs against the vector in the African populations37,38.
BALB/c mice were immunized intramuscularly (i.m.) with multiple heterologous and homologous reg-
imens using ChAd63-PfCSP and emBDES-PfCSP/IL12 at 3-week intervals. Two weeks after boosting, their 
sera were collected and examined for Ab titres against the NANP repeat, which is the immunodominant B-cell 
epitope of PfCSP. Higher Ab titres were induced by ChAd63-PfCSP-prime/emBDES-PfCSP/IL12-boost regi-
men and by emBDES-PfCSP/IL12-prime/ChAd63-PfCSP-boost regimen than the homologous regimen using 
emBDES-PfCSP/IL12, although there was no significant differences between these regimens (Fig. 5A). Cellular 
immune responses in mice were quantified using an ex vivo IFN-γ ELISPOT assay (Fig. 5B). The mean IFN-γ 
SFU per million splenocytes of ChAd63-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen or emBDES-PfCSP/
IL12-prime/ChAd63-PfCSP-boost regimen were 806 or 562, respectively (not statistically different). We then 
did an ICS analysis to quantify the production of various cytokines by a single cell. Our gating strategy for flow 
cytometry focused on either blood CD8+ or CD4+ T cells releasing IFN-γ, tumour necrosis factor α (TNF-α), 
or IL-2, or expressing CD107a, a marker of the degranulation of lymphocytes39,40. As shown in the CD8+ T-cell 
panel in Fig. 6A, emBDES-PfCSP/IL12-prime/ChAd63-PfCSP-boost regimen induced higher total IFN-γ, 
TNF-α, and CD107a (but not IL-2) in response to a pool of overlapping peptides together constituting full-length 
PfCSP. The total frequency of IFN-γ-secreting cells showed a similar tendency to that identified with ELISPOT. 
The CD4+ T-cell panel in Fig. 6B shows that more cells secreted TNF-α after emBDES-PfCSP/IL12-prime/
ChAd63-PfCSP-boost regimen than any other regimen, but there were no significant differences between the cells 
secreted the other cytokines. A Boolean combination gate analysis was performed with the FlowJo software to 
sort the cells into either CD8+ or CD4+ T cells secreting either one, two, or three cytokines (IFN-γ, TNF-α, and/
or IL-2) and/or expressing CD107a after peptide stimulation of PBMC from immunized mice (Supplementary 
Fig. S2). In both cell types, the numbers of single-cytokine-releasing cells were very low and similar. CD8+ T 
cells producing and expressing three markers (IFN-γ, TNF-α, and CD107a) after emBDES-PfCSP/IL12-prime/
ChAd63-PfCSP-boost regimen or after ChAd63-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen showed 
high frequencies, whereas high frequencies of CD4+ T cells expressing CD107a and TNF-α were induced by 
homologous emBDES-PfCSP/IL12 regimen or heterologous emBDES-PfCSP/IL12-prime/ChAd63-PfCSP-boost 
regimen.
Protective efficacy of heterologous ChAd63-PfCSP-prime and emBDES-PfCSP/IL12-boost 
regimens against intravenous (i.v.) sporozoite injection. The protective efficacy of various heter-
ologous or homologous prime-boost regimens using ChAd63-PfCSP and emBDES-PfCSP/IL12 was assessed 
by i.v. challenge with 1,000 transgenic PfCSP@PbCSP (2257cl2) sporozoites expressing full-length PfCSP in 
place of native PbCSP. Consistent with the AdHu5-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen, the 
ChAd63-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen conferred significantly higher sterile protection 
(62.5%) than the other combinations (Fig. 7A). The reverse-ordered vaccination (emBDES-PfCSP/IL12-prime/
Figure 5. PfCSP-specific Abs and cellular immune responses in mice immunized with heterologous prime-
boost regimens using ChAd63-PfCSP and emBDES-PfCSP/IL12. (A) Eight BALB/c mice were immunized 
with the indicated regimens. ChAd63-PfCSP and emBDES-PfCSP/IL12 are shown as ChAd63 and emBDES, 
respectively. Two weeks after boosting, individual sera were collected and the anti-NANP IgG Ab titres were 
measured with an ELISA. (B) Spleens were collected 2 weeks after boosting, and antigen-specific IFN-γ-
secreting T cells were assayed with an ex vivo IFN-γ ELISPOT using the PfCSP-overlapping peptide pool. The 
IFN-γ SFU that reacted with the synthetic peptide per million splenocytes are shown. Bars and error bars 
indicate the means and SD, respectively. The p values were determined with the Mann-Whitney test. *p < 0.05; 
n = 3 or 4.
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Figure 6. Cellular immune responses in mice immunized with heterologous prime-boost regimens using 
ChAd63-PfCSP and emBDES-PfCSP/IL12. BALB/c mice were immunized with the indicated regimens. 
ChAd63-PfCSP and emBDES-PfCSP/IL12 are shown as ChAd63 and emBDES, respectively. Two weeks after 
boosting, individual blood samples were taken and the frequencies of PfCSP-specific CD8+ (A) and CD4+ (B) 
T cells expressing IFN-γ, TNF-α, IL-2, or CD107a that reacted with the PfCSP-overlapping peptide pool were 
assayed with ICS. The results are shown as the percentages of CD8+ and CD4+ T cells secreting each cytokine, 
and bars and error bars indicate means and SD, respectively. The p values were determined with the Mann-
Whitney test. *p < 0.05, **p < 0.01; n = 8.
Figure 7. Protective efficacy in mice immunized with heterologous prime-boost regimens using ChAd63-
PfCSP and emBDES-PfCSP/IL12. BALB/c mice were immunized with two doses (A) (n = 8) or three doses (B) 
(n = 6) of the indicated regimens, and challenged with an intravenous injection of 1,000 transgenic PfCSP@
PbCSP (2257cl2) sporozoites. ChAd63-PfCSP and emBDES-PfCSP/IL12 are shown as ChAd63 and emBDES, 
respectively. Parasitaemiae was monitored for 3 consecutive days, starting from day 5 after challenge, and a 
model predicting the time to reach 1% parasitaemiae was generated. The absence of blood-stage parasites in 
the animals that remained sterilely protected on day 8 was confirmed on day 14 after challenge. The statistical 
analysis was performed with Kaplan-Meier survival curves, and p values were calculated with a Kaplan-Meier 
log-rank (Mantel-Cox) test. ***p < 0.001, **p < 0.01, and *p < 0.05, compared with naïve groups.
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ChAd63-PfCSP-boost regimen) and homologous emBDES-PfCSP/IL12 regimen both showed no protective effi-
cacy. Infected mice immunized with ChAd63-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen showed a sig-
nificant delay in the time to 1% parasitaemiae, with a mean delay of 0.93 days, compared with the mice immunized 
with emBDES-PfCSP/IL12-prime/ChAd63-PfCSP-boost regimen (0.24 days) or homologous emBDES-PfCSP/
IL12 regimen (0.27 days) (Fig. 7A). We performed additional emBDES-PfCSP/IL12 boosting immunization reg-
imens comprising emBDES-PfCSP/IL12 priming followed by emBDES-PfCSP/IL12 and ChAd63-PfCSP boost-
ing (BBC) or ChAd63-PfCSP priming followed by two doses of emBDES-PfCSP/IL12 boosting (CBB) (Fig. 7B). 
Compared with the ChAd63-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen, neither BBC (0%) nor CBB 
(50%) induced further sterile protection, although CBB showed a marked delay in the time to 1% parasitaemiae 
(mean delay of 1.44 days; p = 0.0005).
Discussion
In this study, we have demonstrated that an adenovirus-prime/emBDES-boost regimen induces hybrid immune 
responses consisting of humoral and cellular responses to PfCSP, and affords high sterile protection against sporo-
zoite challenge via two different routes, infectious mosquito bites (77% protection) and the i.v. injection of sporo-
zoites (62.5% protection), under different conditions at various institutes, including Kanazawa University, Imperial 
College London, and the Jenner Institute. In many experiments, challenge with i.v. injection has been preferentially 
used in a range of institutes because the sporozoite dose can be predetermined, even though it is not the natural 
mode of sporozoite infection and does not involve traversal through the skin. Consequently, the i.v. sporozoite chal-
lenge model does not assess the Ab activity induced by vaccines in the skin traversal phase. In contrast, in phase I 
clinical trials, vaccinated volunteers are challenged by infectious mosquito bites and the salivary glands of all the 
blood-engorged mosquitoes are dissected to confirm the presence of sporozoites. However, this process is laborious, 
technically difficult, and time-consuming. Ideally, both routes of sporozoite challenge should be used to evaluate 
vaccine efficacy in an animal model before a clinical trial. The present study demonstrates the high protective effi-
cacy of adenovirus-prime/emBDES-boost regimen using both challenge models. Thus, our consortium has success-
fully developed a new vaccine platform based on ChAd63-prime/emBDES-boost regimen, which were originally 
developed by the Jenner Institute and Kanazawa University, respectively. To our knowledge, this is the first report 
of a malaria pre-erythrocytic vaccine that is highly effective against sporozoite challenge via two different routes.
Heterologous prime-boost vaccination with ChAd63 and MVA expressing the leading pre-erythrocytic anti-
gen, ME-TRAP, is clinically the most potent inducer of CD8+ T cells in humans and the most effective malaria 
vaccine after RTS,S, demonstrating efficacy (defined as sterile protection or delay) in seven of 15 malaria-naive 
volunteers (46.7%) after controlled human malaria infection41. Using the same vaccine platform, ChAd63-MVA 
expressing CSP reduced the liver parasite burden, but the vaccine efficacy was only 26.7% (4/15)41. In BALB/c 
murine models, the ChAd63-prime/MVA-boost regimen has typically shown only modest protective efficacy 
(37.5%) against i.v. inoculation with 1,000 sporozoites42. Using the same i.v. sporozoite challenge reported in 
these previous studies, emBDES boost instead of MVA boost in the present study has increased the protective 
efficacy achieved (62.5%). emBDES has great potential utility in alternative prime-boost combinations with 
adenoviral-vectored vaccine. Moreover, compared with other viral-vectored vaccines, emBDES has several 
advantages as a new vaccine platform, especially from the biological safety perspective, including its (i) low cyto-
toxicity, (ii) inability to replicate in mammalian cells, (iii) absence of pre-existing Abs43, (iv) cost-effectiveness and 
(v) easy manipulation, without an adjuvant formulation44.
A fundamental question is why the adenovirus-prime/emBDES-boost heterologous regimen is more effec-
tive than the emBDES-prime/adenovirus-boost regimen or homologous prime-boost regimen with the same 
vaccines. Generally, booster immunizations increase memory CD8+ T-cell numbers, with the majority of 
these cells displaying an effector phenotype and being localized to the peripheral tissues. However, the mech-
anism that makes heterologous prime-boost more effective than homologous prime-boost is largely unknown. 
A homologous regimen with AdHu5-PfCSP displayed low protective efficacy despite a very high frequency of 
antigen-specific T cells (mean IFN-γ-secreting T-cell count after AdHu5-PfCSP, 2,648). Several reports have 
shown that multifunctional T cells, which can secrete multiple cytokines simultaneously, can contribute to dis-
ease because they secrete more IFN-γ on a per cell basis than monofunctional T cells45,46. However, there was 
no correlation between multifunctional CD4+ or CD8+ T cells and the protection conferred against malaria 
sporozoites in this study. Therefore, we performed extensive immunological analyses using ELISPOT, ICS, and 
ELISA with various peptides, but found no reliable surrogate marker that is strongly linked to the protective effi-
cacy induced by adenovirus-prime/emBDES-boost regimen. We only found that the anti-PfCSP IgG2a induced 
by the AdHu5-PfCSP-prime/emBDES-PfCSP/IL12-boost regimen was higher in the protected mice than in the 
unprotected mice. Mouse IgG2a is known as a cytophilic Ab, which fixes complement and opsonizes pathogens 
for phagocytosis more effectively than IgG147. In humans, high levels of IgG Abs to PfCSP have been detected 
in malaria-endemic populations and these IgG Abs were almost exclusively of the IgG1 and IgG3 subclasses48, 
which have cytophilic activity in cooperation with blood monocytes in the Ab-dependent cellular cytotoxocity 
effect. Consistent with our data, a previous study showed that mice primed with an anti-tuberculosis DNA vac-
cine expressing ESAT6 and boosted with the same recombinant protein increased the IgG2a/IgG1 ratio as well 
as IFN-γ production49. It has been reported that the anti-PfCSP IgG isotypes induced by RTS,S in naïve adults 
were IgG1 and IgG2, and that IgG1 was the dominant subclass, whereas minimal IgG3 and IgG4 responses were 
detected50,51. Therefore, the correlationship between protection and IgG2a suggests that IgG2a is a key factor in 
the protection induced against skin-stage parasites following the mosquito-bite challenge. Further studies should 
focus on the mechanisms exploited by the heterologous prime-boost vaccination approach, particularly the 
innate immune responses induced by subsequent boosting with emBDES.
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In summary, we have demonstrated the potential utility of emBDES vectors as an extremely effective booster 
when combined with adenovirus in a malaria vaccine. The heterologous adenovirus-prime/emBDES-boost reg-
imen shows great potential in inducing unique immune responses, conferring improved immunogenicity and 
protection against sporozoites delivered by both mosquito-bite and i.v. injection. This study is the first step toward 
the development of a new malaria vaccine platform based on adenovirus-prime/emBDES-boost immunization 
regimen. It will also be very interesting to apply this vaccine platform to other infectious diseases that have an 
intracellular stage, as well as malaria parasites.
Materials and Methods
Animals, cell lines, peptides, and parasites. Female inbred BALB/c (H-2d) mice were used to assess 
immunogenicity and protection. Spodoptera frugiperda (Sf9) and HEK293A cells were maintained as described 
previously10. Recombinant PfCSP (rPfCSP) was produced in Escherichia coli, as described previously10. The syn-
thetic peptides (NANP6C repeat, NYDNAGTNL, and 20-mer peptide pools overlapping PfCSP by 10 amino 
acids) have been described previously10,52. Transgenic P. berghei lines expressing the full-length PfCSP gene of 
strain 3D7, designated PfCSP-Tc/Pb and PfCSP@PbCSP (2257cl2) [(PbANKA-PfCSP(r)PbCSP GFP::LucPbeef1a; 
line RMgm-4110; www.pberghei.eu) have been described previously53,54.
Ethics statement. All animal care and handling procedures were approved by the Animal Care and Ethical 
Review Committee of Kanazawa University (no. 22118–1). All procedures were performed in accordance with the 
UK Animals (Scientific Procedures) Act (PPL 70/8788, Imperial College; PPL 30/2414, Oxford). All activities at 
Imperial College were approved by the Imperial College’s Animal Welfare and Ethical Review Body.
Recombinant viral vaccines. BDES-sPfCSP2-WPRE-Spider, BES-mIL-12-Spider, and BES-GL3 have 
been described previously16,17. In this paper, the BDES-sPfCSP2-WPRE-Spider and BDES vaccines consisting of 
BDES-sPfCSP2-WPRE-Spider and BES-mIL-12-Spider are described as emBDES-PfCSP and emBDES-PfCSP/
IL12, respectively. To generate the AdHu5-PfCSP, the gene cassette encoding GPI-anchor lacking PfCSP 
(Leu19-Val377) fused to the VSV-G protein membrane anchor sequence, followed by a wpre sequence, was 
excised from pFast-sPfCSP2-WPRE-Spider16 by digestion with EcoRI and XhoI and then inserted into the 
EcoRI and XhoI sites of pAd/PL-DEST (Invitrogen, Carlsbad, CA, USA) under the control of the CAG promoter 
sequence. The adenovirus was purified and titrated with the Fast-Trap Adenovirus Purification and Concentration 
Kit (Millipore, Temecula, CA, USA) and the Adeno-X™ Rapid Titer Kit (Clontech, Palo Alto, CA, USA), respec-
tively, according to the manufacturers’ protocols. ChAd63-PfCSP encoding PfCSP (Leu19-Ser383) sequence 
has been described previously55. All PfCSP genes inserted into BDES-sPfCSP2-WPRE-Spider, AdHu5-PfCSP, or 
ChAd63-PfCSP were codon optimized.
In vivo bioluminescent imaging. Luciferase-expressing BES-GL3 was administered into the right tibi-
alis anterior muscle of BALB/c mice (n = 3; 1 × 108 pfu/mouse) on day 0, and at the appropriate time points, 
d-luciferin (15 mg/ml; OZ Biosciences, Marseille, France) was administered intraperitoneally (150 μl/mouse). 
After 10 min, the animals were anesthetized with a ketamine (100 mg/kg)/xylazine (10 mg/kg) mixture, and the 
luciferase expression was detected with an IVIS® Lumina LT in vivo imaging system (PerkinElmer, Waltham, MA, 
USA). The luciferase expression decreased to an undetectable level by day 42, and BES-GL3 was re-administered 
into the left tibialis anterior muscle 14 days later (day 56). Luciferase expression was detected as described above. 
To quantify the luminescence, the region on the captured images was selected, and the luminescence output was 
analysed with the Living Image software and expressed as the total flux (photons/second). The relative total flux 
was calculated after the maximum total flux at 3 h defined as 100% and the background total flux was defined as 
0%.
Immunoblotting and IFA assay. All immunoblotting and IFA-related methods used are described in the 
Supplementary Information.
ELISA. Sera from the immunized mice were collected as tail blood samples 2–3 weeks after the first and 
second immunizations and one day before challenge. PfCSP-specific Ab levels were quantified with an ELISA. 
EIA/RIA plates (Corning Inc.; Corning, NY, USA) pre-coated with GPI-anchor-truncated recombinant PfCSP 
(rPfCSP; 0.4 µg/well)10 or the synthesized repeated-NANP6C-sequence peptide (0.1 µg/well) were blocked with 
1% bovine serum albumin in phosphate-buffered saline (PBS) and incubated with serial dilutions of sera from 
the immunized and control mice. To determine the anti-PfCSP isotype IgG Ab titres, the total IgG, IgG1, IgG2a, 
and IgG2b titres were measured with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibodies. 
The endpoint titres were expressed as the reciprocal of the last dilution that gave an optical density at 414 nm 
of 0.15 U above the value of the negative control (<0.1). To determine the anti-PfCSP NANP IgG Ab titres, 
the total IgG titre was measured with an alkaline-phosphatase-conjugated goat anti-mouse whole-IgG antibody. 
The results were expressed in ELISA units (EU). A 1:14,000 dilution (63.6 ng/ml) of mouse anti-PfCSP NANP 
mAb 2A10 had an EU of exactly 1. All the mice used were seronegative before immunization. To determine the 
anti-baculovirus IgG Ab titres, the total IgG titres were measured with an HRP-conjugated goat anti-mouse IgG 
antibody. The endpoint titres were expressed as the reciprocal of the last dilution that gave an optical density at 
414 nm of 0.15 U above the value of the negative control (<0.1).
Ex vivo IFN-γ ELISPOT assay. Ammonium chloride potassium lysing buffer (ACK)-treated splenocytes 
were cultured for 20–24 h on MAIP ELISPOT plates (Mabtech, Stockholm, Sweden) or BD ELISPOT plates (BD 
Bioscience, San Jose, CA) with the immunodominant H-2Kd-restricted T-cell epitope (NYDNAGTNL, PfCSP39-47; 
final concentration, 1 µg/ml) or the PfCSP-overlapping peptide pool (final concentration, 5 µg/ml). The IFN-γ 
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ELISPOT assay was conducted with coating and detecting mAbs from the IFN-γ ELISPOT ALP Kit (Mabtech) 
or the BD™ IFN-γ ELISPOT Set (BD Biosciences), according to the manufacturer’s protocol. Spots were counted 
with an ELISPOT plate counter (Autoimmun Diagnostika, Strassberg, Germany) and expressed as IFN-γ SFU 
per million splenocytes, after the background subtraction of wells containing cells and medium, but no peptide.
Intracellular cytokine staining (ICS). ICS was performed with splenocytes and peripheral blood 
mononuclear cells (PBMCs), as described previously30. The splenocytes were stimulated with a final concen-
tration of 1 µg/ml of the immunodominant CD8+ T-cell epitope NYDNAGTNL (PfCSP39-47) and 1 µg/ml 
of GolgiPlug™ (BD Biosciences) in a 96-well U-bottom tissue culture plate (Corning Inc.) for 6 h. The cells 
were then surface stained with anti-mouse CD16/32 Ab, Pacific Blue™-conjugated anti-mouse CD4 Ab, and 
PerCP/Cy5.5-conjugated anti-mouse CD8α Ab, and the cytokine was stained with fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse IFN-γ Ab or a FITC-conjugated rat IgG1κ Isotype control Ab. Data were acquired 
with a BD FACSVerse™ Flow Cytometer (BD Biosciences) and analysed with FlowJo (Tree Star, Ashland, OR, 
USA). All Abs were purchased from BioLegend (San Diego, CA, USA). The PMBCs were stimulated with a 
final concentration of 5 µg/ml of the PfCSP-overlapping peptide, 1 µg/ml of GolgiPlug™ (BD Biosciences), and 
phycoerythrin-conjugated anti-mouse CD107a Ab in a 96-well U-bottom tissue culture plate (Corning Inc.) 
for 6 h. The cells were then surface stained with anti-mouse CD16/32 Ab, eFluor-450-conjugated anti-mouse 
CD4 Ab, and PerCP-cyanine5.5-conjugated anti-mouse CD8α Ab, and the cytokines were stained with 
allophycocyanin-conjugated anti-mouse IFN-γ Ab, Alexa-Fluor-488-conjugated anti-mouse TNFα Ab, and 
PE-cyanine7-conjugated anti-mouse IL-2 Ab. The data were acquired with a BD LSR II Flow Cytometer (BD 
Biosciences) and analysed with the FlowJo software. All Abs were purchased from eBioscience.
Immunization and challenge infections. Protective efficacy of heterologous AdHu5-PfCSP-prime/
emBDES-PfCSP/IL12-boost immunization against mosquito-bite challenge. Balb/c mice were immunized i.m. 
twice, with a 3-week interval between the primary and booster immunizations. The doses of vaccines were 
100 µl containing 5 × 107 plaque-forming units (pfu) for AdHu5-PfCSP and 100 µl containing 2 × 108 pfu for 
emBDES-PfCSP/IL12. Two weeks after the booster immunization, the mice were challenged with bites of 
PfCSP-Tc/Pb-infected mosquitoes, as described previously10. Briefly, infected mosquitoes were allowed to feed 
on the abdomen of each mouse for 15 min. To ensure a high probability of baseline infection (in the control 
mice), all the mice received a minimum of two bites and a maximum of seven bites. The salivary glands from all 
the blood-engorged mosquitoes in the control group were dissected to confirm the presence of sporozoites, indi-
cating a potentially infective bite. Where necessary, mosquito biting was performed repeatedly until 2–7 infected 
mosquitoes had bitten each mouse. The mice were checked for P. berghei blood-stage infection with a microscopic 
examination of Giemsa-stained thin smears of their tail blood, prepared on days 5, 7, 9 11, and 14 after challenge. 
A minimum of 20 fields (magnification, ×1,000) were examined before a mouse was deemed to be negative for 
infection. Protection was defined as the complete absence of blood-stage parasitaemiae on day 14 after challenge.
Protective efficacy of heterologous ChAd63-prime/emBDES-boost immunization against intravenous sporozoite 
challenge. Balb/c mice were immunized i.m. twice, with a 3-week interval between the primary and booster 
immunizations. The doses of vaccines were 50 µl containing 1 × 108 pfu for ChAd63-PfCSP and 100 µl containing 
2 × 108 pfu for emBDES-PfCSP/IL12. Two weeks after the booster immunizations, the mice were challenged 
with 1,000 PfCSP@PbCSP (2257cl2) sporozoites via the i.v. route into the tail vein, as described previously30. 
In a parallel experiment, Balb/c mice were immunized three times at 3-week intervals via the i.m. route, and 
were challenged with sporozoites via the i.v. route 8 days after the final immunization. The mice were checked 
for P. berghei blood-stage infection by the microscopic examination of Giemsa-stained thin smears of their tail 
blood, prepared on days 5, 6, 7, 8, 11, and 14 after challenge. The time required to reach 1% parasitaemiae was 
determined as described previously34. A minimum of 20 fields (magnification, ×1,000) were examined before a 
mouse was deemed to be negative for infection. Protection was defined as the complete absence of blood-stage 
parasitaemiae on day 14 after challenge.
Statistical analysis. A two-tailed Fisher’s exact probability test was performed to determine the signifi-
cance of differences in the protective efficacies of the vaccines, using the SPSS software (version 19, Chicago, 
IL, USA). In all other experiments, statistical differences between the experimental groups were analysed by the 
methods described in the individual figure legends; p values of <0.05 were considered statistically significant. 
Statistical analyses were performed with either Prism version 7.0a (GraphPad Software Inc., La Jolla, CA, USA) 
or Microsoft® Excel (Radmond, WA, USA).
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